Cronos Group And Ginkgo Bioworks Achieve Rare Cannabinoid THCV Equity Milestone

Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) and Ginkgo Bioworks (NYSE: DNA) achieved the third target productivity milestone in their partnership to produce eight cultured cannabinoids.

Using Ginkgo's platform for organism design and development, Cronos has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid hypothesized to reduce the appetite-enhancing property of THC. Access to additional rare cannabinoids will support Cronos' innovation pipeline and commercialization strategy.

Launched in 2018 with the goal of accessing rare molecules in …

Full story available on Benzinga.com

More Cronos Group And Ginkgo Bioworks Achieve Rare Cannabinoid THCV Equity Milestone